胃がんに対するTS-1の補助化学療法試験（ACTS-GC）

基本情報

NCT ID

NCT00152217

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

1,000

治験依頼者名

Taiho Pharmaceutical Co., Ltd.

概要

This controlled study is designed to evaluate the efficacy of TS-1 on survival compared with surgery alone. Patients will be randomly assigned to receive either surgery alone or surgery followed by treatment with TS-1 within 45 days after curative resection (curability A or B). To assess the efficacy, data on recurrence and survival will be collected from the time of enrollment until 5 years after surgery. To evaluate safety, data on adverse events will be collected from the time of enrollment until 1 year after surgery.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)